Immune Response to Pneumococcal Polysaccharide Vaccine (23-valent) Predicts Asthma Status and Outcomes in Late Adolescents With Asthma
Study Details
Study Description
Brief Summary
Advisory Committee for Immunization Practices (ACIP) from the Centers for Disease Control (CDC) recommends that children (6-18 years) and adults (≥19 years old) with chronic lung condition such as asthma or cigarette smoking be vaccinated with Pneumococcal vaccine (PPSV23). The purpose of this study is to increase awareness of vaccination to late adolescents with asthma and smokers (social aspect of study), and to recommend vaccination (which is the clinical aspect). Individuals who agree to receiving vaccine will be enrolled in research to determine whether late adolescents with and without asthma (smokers) have distinctive pneumococcal vaccine response patterns and whether such patterns are associated with subsequent variance in asthma outcomes.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 1 |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Asthmatics 19-20 year old asthmatics who agree to participate in study will have serum collected for analysis. PPSV23 vaccine [Pneumonococcal Polysaccharide Vaccine 23-valent (PPSV-23)] will be offered per the ACIP/CDC guidelines. Those who agree to receive the vaccine will have a second draw for serum 4-6 weeks post vaccination for immunization response. They will also be follow up after 1 year to assess for asthma control and outcomes. This arm will additionally allow for comparison of asthma outcomes and vaccine response |
Biological: Pneumonococcal Polysaccharide Vaccine 23-valent (PPSV-23)
Other Names:
|
| Active Comparator: Non-asthmatics 19-20 year old non-asthmatic smokers who agree to participate in study will have serum collected for analysis. PPSV23 vaccine [Pneumonococcal Polysaccharide Vaccine 23-valent (PPSV-23)] will be offered per the ACIP/CDC guidelines. Those who agree to receive the vaccine will have a second draw for serum 4-6 weeks post vaccination for immunization response. This arm will allow for comparison of vaccine response between asthmatics and non-asthmatics (smokers) |
Biological: Pneumonococcal Polysaccharide Vaccine 23-valent (PPSV-23)
Other Names:
|
| Other: Asthmatics - Serum Stored Once the accrual for the experimental arm is met, 19-20 year old asthmatics who wish to participate in study will have serum collected for analysis. PPSV23 vaccine [Pneumonococcal Polysaccharide Vaccine 23-valent (PPSV-23)] will be offered per the ACIP/CDC guidelines. This arm will allow for study of baseline vaccine titers to pneumococcus in asthmatics at same time increase the vaccine uptake in the community. |
Biological: Pneumonococcal Polysaccharide Vaccine 23-valent (PPSV-23)
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Change in asthma Control Status [approximately 1 year]
Change in asthma control status will be assessed at end of 1 year follow up. Included would be Asthma Control Test (ACT) Score
Secondary Outcome Measures
- Comparison of PPSV23 vaccine serotype specific antibody response between asthmatic and non-asthmatic smokers [Vaccine response will be measured at 4 to 6 weeks after administration of vaccine]
Vaccine response in form of serotype titers to pneumococcal antigens will be measured 4-6 weeks after vaccination and post vaccine titers will be compared with pre-vaccine titers between asthmatics and non-asthmatics (smokers)
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Reside in Olmsted County, Minnesota (defined by Olmsted County address in medical record within one year prior to last follow-up date as of data abstraction)
-
Receive medical care from Mayo Clinic clinical practice
-
Signed research authorization for using medical record for research
Exclusion Criteria:
-
Diagnosis of an immunodeficiency (primary and secondary)
-
Previous or current diagnosis of a Rheumatological disorders (Rheumatoid arthritis, Lupus, Sjögren, and vasculitis), cancer (chronic lymphocytic leukemia, non-Hodgkin lymphoma, and B-cell malignancy), diabetes, active infection (pneumonia, otitis media, HIV, and EBV), other chronic diseases (multiple sclerosis, etc), renal disease such nephritic syndrome, and protein losing enteropathy
-
Current or previous use (within the last 6 months) of systemic corticosteroids, and other immunosuppressive agents (cyclosporin, methotrexate, and mycophenolic acid)
-
Vaccination of PPSV-23 (receiving childhood pneumococcal vaccination during infancy is eligible for this study)
-
Pregnancy
Enrollment will be delayed 2 weeks for those subjects that can be included but have upper respiratory infection or viral illness to allow for natural resolution.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Mayo Clinic | Rochester | Minnesota | United States | 55905 |
Sponsors and Collaborators
- Rohit Divekar
Investigators
- Principal Investigator: Rohit Divekar, MBBS, PhD, Mayo Clinic
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 15-005581